COLLIERVILLE, Tenn., October 29, 2021 – Atheneum Oncology Foundation, a nonprofit
an organization that provides administrative support and educational resources to the community
oncology practices, announces that G1 Therapeutics, Inc. has signed on as a sponsor of The
Oncology Circle, a non-profit alliance of 25 independent, physician-owned, oncology practices
supported by Atheneum.
“G1 Therapeutics has partnered with The Oncology Circle to help ensure that community
oncology practices receive resources and information they need to maintain their
independence and navigate the rapidly evolving economic and political environment in which
healthcare operates,” said John Ogle, Executive Director of Atheneum. “We’re thrilled to have
G1 Therapeutics as a supporter and welcome their participation in our semi-annual meetings,
which serve as an independent forum for members to openly discuss key areas of importance
to community oncology practices.”
Meeting topics are generated by practice members and include areas such as clinical best
practices, executive roundtable discussions, Medicare coding, negotiation tactics, and new
tools and technologies that facilitate practice efficiency. Meetings are designed to provide
actionable knowledge to help practices implement and execute viable strategies to improve the
clinical, operational, and financial management of their practices.
“The majority of cancer patients are treated in community oncology practices across the nation,
so it is imperative that the pharmaceutical industry supports the Foundation’s mission to
expand the tools and resources that practices need to be successful on behalf of their patients,”
said Joe Wornson, Senior Director Distribution and Provider Networks at G1 Therapeutics.
“Being a part of The Oncology Circle brings us together with member practices so we can learn
from them about the challenges they face and help facilitate the sharing and transfer of
knowledge and information.”
The fall meeting of The Oncology Circle was held Sept. 24-25 and focused on small-cell-lung
cancer and newly approved therapies to treat and support patients with SCLC.
About The Oncology Circle
The Oncology Circle is a membership-based, knowledge sharing, collaboration among
independent, professionally managed, physician-owned oncology practices. Its goal is to
promote discovery and adoption of best practices among the members to improve the clinical,
operational, and financial competence of community oncology practices through collaborative
meetings, development of financial and operational benchmarks, and sharing best practices.
The Oncology Circle was formed in 2003 and was acquired by Atheneum Oncology Foundation,
Inc. (a tax-exempt, 501(c)(3) organization) in 2020. It is funded by support from pharmaceutical
and equipment manufacturers, supply chain distributors, consultants, and other businesses
that are directly providing goods and/or services for use in oncology.
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the
development and commercialization of next generation therapies that improve the lives of
those affected by cancer, including the Company’s first commercial product, COSELA™
(trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan
evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder
cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information,
please visit us here and follow us on Twitter.
G1 Therapeutics™ and the G1 Therapeutics logo and COSELA™ and the COSELA logo are
trademarks of G1 Therapeutics, Inc.
Contact
John D. Ogle
Executive Director, Atheneum Oncology Foundation
901-574-2635
jogle@ogleclinton.com
Rebecca Levine
Director, Corporate Communications and Public Relations
(919) 667-8711
rlevine@g1therapeutics.com
